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Outcomes for patients with peripheral T-cell lymphoma (PTCL) are generally poor with 35-40% 5-year 
survival using CHOP-like chemotherapy. Addition of other agents to CHOP has not consistently 
improved outcomes and can cause excess toxicity 1,2; new approaches are urgently needed. 
Favourable outcomes have been achieved with autologous stem cell transplant consolidation (ASCT) 
in some settings with long term survival rates exceeding 50%, particularly for those transplanted in 
first complete remission 3.  
 
EATL is a rare form of T-cell lymphoma with an incidence of 0.1/100,000 per year in Western Europe 
4. EATL poses a number of diagnostic and therapeutic challenges, as patients frequently present with 
poor performance status, malnutrition and acute abdominal complications. There is no established 
standard of care and outcomes are inferior to other T-cell lymphomas with 5-year failure free survival 
of <5% 5-7. We have previously reported the use of intensive chemotherapy followed by ASCT in a 
retrospective population-based study of patients with EATL 4. These favourable results encouraged us 
to prospectively assess the feasibility of this approach in a multi-centre setting for aggressive T-cell 
lymphoma. 
 
Patients with histologically confirmed, previously untreated EATL aged ≥18 years were eligible for 
entry into this single arm phase 2 trial. In light of emergent data on ASCT in PTCL and to increase 
recruitment, the protocol was amended to allow inclusion of patients with PTCL, ALK-negative 
anaplastic large cell lymphoma (ALCL) and extranodal NK/T-cell lymphoma (ENKTL). Performance 
status (PS) was permissive but patients had to be deemed able to tolerate the intensive treatment 
regimen by the treating clinician. Exclusion criteria included severe cardiac, renal or liver dysfunction. 
Disease was staged using Lugano (EATL patients) or Ann Arbor (all other patients) staging systems. 
Central histopathology review was undertaken in Newcastle upon Tyne Hospitals NHS Foundation 
Trust.  Written informed consent was obtained prior to study entry. 
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Patients received 1 cycle of CHOP chemotherapy (cyclophosphamide, doxorubicin, vincristine and 
prednisolone), followed by 3 cycles of IVE (ifosfamide 1500mg/m2 days 1-3, etoposide 200mg/m2 
days 1-3 and epirubicin 50mg/m2 day 1), with intermediate dose methotrexate (MTX, 1.5 mg/m2) 
administered on day 22 of each 28 day cycle (see Figure 1) 4. Peripheral blood stem cells were 
harvested after either 2 or 3 courses of IVE. Patients achieving CR after IVE-MTX, received high dose 
therapy with BEAM (carmustine, etoposide, cytarabine and melphalan) followed by ASCT 4. Patients 
achieving partial response (PR) could also receive ASCT on trial at the investigator’s discretion. 
 
The primary endpoint was 1-year overall survival (OS) for EATL patients. With 80% power and 5% 2-
sided alpha, 60 patients would be required to detect an improvement in 1-year OS from 31% to 54% 
in EATL.  Secondary endpoints included toxicity and regimen feasibility across multiple sites. Response 
was assessed at the end of IVE-MTX induction by contrast-enhanced computed tomography (CT) 
and/or by endoscopy and biopsy, according to standard criteria 8.  
 
Twenty-one patients were enrolled at 10 UK sites between September 2009 and July 2014; target 
recruitment was not reached. Clinical characteristics are detailed in Table 1. Median age was 55 years 
(31-71 years). Six patients (29%) required laparotomy at diagnosis; all patients had measurable disease 
at study entry.   
 
All patients received 1 cycle of CHOP chemotherapy. Eighteen patients (86%) completed 3 cycles of 
IVE and 15 patients (71%) completed 3 cycles of methotrexate. Grade 3-5 toxicity is detailed in Table 
2. One patient (5%) discontinued trial therapy due to grade 3 encephalopathy with ifosfamide. Four 
patients (19%) required dose reductions for at least 1 cycle of IVE chemotherapy, mostly due to 
haematological toxicity. There were 2 fatal events during induction therapy: 1 neutropaenic sepsis, 
and 1 sudden death deemed due to pre-existing epilepsy +/- type 1 diabetes, which occurred 16 days 
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after completing the final IVAC cycle with no preceding symptoms to suggest ifosfamide 
encephalopathy. This was not felt to be treatment-related.  
 
Following completion of IVE-MTX induction therapy, 10 patients (48%) achieved CR and 5 (24%) 
achieved PR, with an overall response rate of 71% for the whole cohort. Three patients (14%) had 
progressive disease (PD) and 3 (14%) were not assessable due to death or study withdrawal. Similar 
response rates were achieved in the EATL cohort, with CR in 6 patients (55%), PD in 2 (18%) and not 
assessable in 3 (27%).  
 
Of the 15 patients that responded to IVE-MTX, 2 (13%) failed to mobilise sufficient stem cells, 
precluding planned autograft. In total, 13 patients (62%) proceeded to ASCT, including 5 of 11 (45%) 
EATL patients.  Five PTCL patients in PR after induction chemotherapy continued to ASCT at the 
clinicians’ discretion, of which 2 (40%) subsequently achieved CR.  
 
Median follow-up was 27 months. Survival curves are shown in Figure 1. One-year OS and PFS for the 
whole cohort were 62% (95% confidence interval (CI): 38 – 79) and 48% (95% CI: 26 – 67), respectively. 
Median PFS was 12 months and median OS has not been reached. For EATL patients, 1-year OS and 
PFS were both 45% (95% CI: 17 – 71). Of the 5 EATL patients receiving ASCT, only 1 has relapsed. Two 
of 3 patients with presumed type 2 EATL (monomorphic epitheliotropic intestinal T-cell lymphoma) 
progressed during IVE-MTX and died of lymphoma; the other is alive and disease-free. Of those with 
type 1 EATL, 4 are alive and lymphoma-free, 2 have relapsed from CR and 2 died during IVE-MTX. 
 
For non-EATL patients, 1-year OS and PFS were 80% (95% CI: 41 – 95) and 50% (95% CI: 18 – 75), 
respectively. For the 13 patients (EATL and PTCL) that completed protocol treatment and received 
ASCT, the 1-year PFS and OS from time of ASCT were 54% (95% CI: 25 – 76) and 85% (95% CI: 51 – 96), 
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respectively. Nine deaths have been reported in total; 7 due to lymphoma, 1 treatment-related and 1 
due to other causes. 
 
This study demonstrates that IVE-MTX therapy and ASCT for frontline treatment of T-cell lymphoma 
can be delivered in a multi-centre setting, with a toxicity profile that is manageable and no greater 
than expected for this dose intense regimen and challenging patient cohort.  
 
Although underpowered, this study provides important prospective evidence supporting use of IVE-
MTX and ASCT for EATL, where outcomes have historically been poor and there is a paucity of evidence 
to support alternative regimens. We previously reported a 5-year PFS and OS of 52% and 60%, 
respectively, with the same regimen in a retrospective study of 26 EATL patients 4, whilst 1-year PFS 
and OS were both 45% in this study. Follow-up in our study is relatively short, although relapses after 
ASCT tend to occur within 18 months of ASCT 9. The only other prospective trial to report outcomes 
for EATL patients with frontline ASCT is the Nordic Lymphoma Group NLG-T-01 study. Twenty-one 
EATL patients were treated with biweekly CHOP-etoposide followed by BEAM or BEAC-conditioned 
ASCT, with a 5-year PFS and OS of 38% and 48%, respectively 3. Notwithstanding the limitations of 
making comparisons with historical data, the results of these studies together compare favourably 
with a 5-year OS without ASCT of 20-28% 4,5. A retrospective European Group for Blood and Marrow 
Transplantation (EBMT) study of ASCT for EATL demonstrated superior outcomes for patients 
receiving ASCT in first remission, with a 4-year OS was 66% compared to 36% for those in later 
remission 9. Together, these data support use of frontline ASCT for eligible EATL patients. 
 
Ifosfamide/etoposide-based regimens are commonly used in frontline treatment of NK/T-cell 
lymphoma 10 and retrospective data suggest that IVE-MTX has efficacy in frontline treatment of PTCL 
11. This study demonstrates that IVE-MTX has activity against PTCL but further evidence is needed to 
support its use as frontline therapy for PTCL subtypes other than EATL. Our results are broadly in line 
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with other studies that incorporate up-front ASCT consolidation for PTCL 12, including the NLG-T-01 
study, which reported a 3-year PFS and OS of 48% and 56% with CHOP-etoposide and ASCT 3. 
 
The majority of patients in this study had a PS of 0-1, reflecting the requirement to make a judgement 
prior to trial registration regarding potential eligibility for ASCT.  Although often impaired at diagnosis, 
PS may improve with successful treatment of EATL and retrospective data show that those with PS >1 
at presentation may later become eligible for ASCT 4. Fitness, PS and age may have impeded 
recruitment to some extent, with approximately 60 expected cases per year in the UK. However, it 
was also clear from discussions with UK-based haemato-oncologists that many were using IVE-MTX 
and ASCT for eligible patients off-trial whilst focusing research resources on trials in more common 
malignancies. Only 10 sites of an originally anticipated 30 recruited to this trial and funding was not 
available for extended recruitment. Well-designed prospective disease registries and/or international 
collaboration will be essential for future studies in EATL. 
 
In summary, EATL is a rare lymphoma with extremely poor outcomes and no established standard of 
care. This trial provides prospective evidence, supporting previously published retrospective data 4, 
demonstrating that IVE-MTX followed by ASCT is a feasible and effective regimen for the treatment of 
EATL.  
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Table 1:  Baseline Clinical Characteristics 
 
Baseline characteristics 
N (%) 
N=21 
Age (years)   
Median (range) 55 (31 to 71) 
Sex   
Female 7 (33%) 
ECOG performance status    
0 11 (52%) 
1 9 (43%) 
2 1 (5%) 
Diagnosis   
Intestinal T-cell Lymphoma/Enteropathy-type T-cell Lymphoma 11 (52%) 
Peripheral T-cell Lymphoma, not otherwise specified 8 (38%) 
ALK negative Anaplastic T-cell Lymphoma 1 (5%) 
Extranodal nasal NK/T-cell Lymphoma 1 (5%) 
History of coeliac disease (EATL patients only: N=11) 
Absent 3 (27%) 
Present 8 (73%) 
Lugano staging system (EATL patients only: N=11)   
I 5 (45%) 
II-1 3 (27%) 
II-E 1 (9%) 
IV 2 (18%) 
Bulky disease (any tumour mass > 5cm) (EATL patients only: N=11)   
Absent 8 (73%) 
Present 1 (9%) 
Unknown 2 (18%) 
Staging – Ann Arbor Staging Criteria (non-EATL patients: N=10)   
I 1 (10%) 
II 1 (10%) 
III 4 (40%) 
IV 4 (40%) 
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 Treatment phase 
All phases (n=21)  CHOP (n=21) IVE/MTX (n=21) ASCT (n=13) 
Infection     
Infection and febrile 
neutropaenia 3 (14%) 13 (62%) 10 (77%) 17 (81%) 
Haematological     
Neutropaenia 10 (48%) 18 (86%) 12 (92%) 21 (100%) 
Leukopaenia 1 (5%) 3 (14%) 2 (15%) 4 (19%) 
Thrombocytopaenia 0 10 (48%) 13 (100%) 17 (81%) 
Anaemia 1 (5%) 8 (38%) 3 (23%) 11 (52%) 
Gastrointestinal     
Diarrhoea 0 0 5 (38%) 5 (24%) 
GI perforation 1 (5%) 2 (10%) 0 3 (14%) 
Nausea and vomiting 0 1 (5%) 1 (8%) 2 (10%) 
GI haemorrhage 0 1 (5%) 0 1 (5%) 
Other GI 2 (10%) 0 0 2 (10%) 
Other systems     
Cardiac  1 (5%) 2 (9%) 0 2 (9%) 
Hypotension 1 (5%) 0 1 (8%) 2 (10%) 
Pulmonary 1 (5%) 1 (5%) 1 (8%) 3 (14%) 
Hypokalaemia 1 (5%) 3 (14%) 1 (8%) 4 (19%) 
Raised ALT 0 2 (10%) 0 2 (10%) 
Encephalopathy 0 1 (5%) 0 1 (5%) 
Renal dysfunction 0 1 (5%) 2 (15%) 2 (10%) 
 
Table 2: Grade 3-5 adverse events according to treatment phase (all patients) 
Includes all events occurring in 2 or more patients, and all gastrointestinal toxicity. ALT= alanine 
transaminase, GI= gastrointestinal. Toxicity was assessed according to the National Cancer Institute 
Common Terminology Criteria for Adverse Events version 3.0. 
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Figure 1: Patient outcomes- overall survival (A) and progression-free survival (B) for the whole 
cohort, and overall survival according to diagnosis (C) 
 
 
